Zobrazeno 1 - 10 of 100 pro vyhledávání: '"C. Germa"'
1
Akademický článek
Artificial intelligence-based prediction of neurocardiovascular risk score from retinal swept-source optical coherence tomography–angiography
Autor: C. Germanese, A. Anwer, P. Eid, L.-A. Steinberg, C. Guenancia, P.-H. Gabrielle, C. Creuzot-Garcher, F. Meriaudeau, L. Arnould
Publikováno v: Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract The recent rise of artificial intelligence represents a revolutionary way of improving current medical practices, including cardiovascular (CV) assessment scores. Retinal vascular alterations may reflect systemic processes such as the presen
Externí odkaz: https://doaj.org/article/24e9c440dcf24041a3d81e6379c16769
Zobrazit plný text záznamu
3
Abstract P5-21-28: Phase Ib study of ribociclib + letrozole in Asian non-Japanese patients with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESASIA
Autor: J Chiu, Y Han, Yoon Sim Yap, C Germa, J Suarez-Vizcarra, Yoshinori Ito, X Liu
Publikováno v: Cancer Research. 78:P5-21
Background: First-line ribociclib (RIB; a selective cyclin-dependent kinase 4/6 inhibitor) + letrozole (LET) significantly prolonged progression-free survival vs placebo + LET in patients (pts) with hormone receptor-positive (HR+), human epidermal gr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::36b94dce56ae992da1042e705e1dad6c
https://doi.org/10.1158/1538-7445.sabcs17-p5-21-28
Zobrazit plný text záznamu
5
Abstract P1-14-05: Ribociclib dose recommendations for potential pharmacokinetic drug interaction and in special patient populations with organ impairment
Autor: Marc Laisney, Shu Yang, Tanay S. Samant, Martin Mueller-Zsigmondy, Mohamed Elmeliegy, Ahmed M. Abdelhady, Abhijit Chakraborty, Michelle Quinlan, K-I. Umehara, Yen-Shen Lu, X Liu, Felix Huth, C. Germa
Publikováno v: Cancer Research. 78:P1-14
Background: Ribociclib (Kisqali®) is a CDK4/6 inhibitor, recently approved in the U.S. as a first line therapy for HR+/HER2- advanced breast cancer (ABC) in combination with an aromatase inhibitor. The recommended starting dose is 600 mg/day orally
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cd9b1be09aa2993dd96d6bb5f9873bfd
https://doi.org/10.1158/1538-7445.sabcs17-p1-14-05
Zobrazit plný text záznamu
6
Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations
Autor: S. Dhuria, Felix Huth, Shu Yang, Mohamed Elmeliegy, C. Germa, Marc Laisney, Arnaud Grandeury, Martin Mueller-Zsigmondy, Yasong Lu, Tanay S. Samant, Michelle Miller, Kenichi Umehara
Publikováno v: Clinical Pharmacology and Therapeutics
Ribociclib (KISQALI), a cyclin-dependent kinase 4/6 inhibitor approved for the first-line treatment of HR+/HER2- advanced breast cancer with an aromatase inhibitor, is administered with no restrictions on concomitant gastric pH-elevating agents or fo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e83dd5ac4a4c47714d9ece162a5fe2e
http://europepmc.org/articles/PMC6099197
Zobrazit plný text záznamu
7
Akademický článek
TRÁNSITO REPETIDO SOBRE LA MISMA HUELLA: EFECTO EN LAS PROPIEDADES FISICAS DE UN ARGIUDOL TÍPICO
Autor: Guido Bellora, Luis Alberto Lozano, C. Germán Soracco, Facundo Guilino, Nicolas Polich, María Paz Salazar, Rafael Villarreal, Telmo Palancar
Publikováno v: Ciencia del Suelo, Vol 41, Iss 1, Pp 1-16 (2023)
Resumen Con el aumento de la masa de las máquinas y el tránsito repetido se han ido incrementando los problemas de compactación. Además, frecuentemente se transitan los lotes en condiciones de baja capacidad portante generando una compactación s
Externí odkaz: https://doaj.org/article/9d1209975c824904bb96fa017b18f01b
Zobrazit plný text záznamu
8
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial
Autor: Lowell L. Hart, Cristian Villanueva, Deborah Lindquist, Erik Jakobsen, Carlos L. Arteaga, Joseph T. Beck, Farida Souami, Gabriel N. Hortobagyi, Katarína Petráková, Pierfranco Conte, Joyce O'Shaughnessy, C. Germa, David Cameron, Gabe S. Sonke, S. Mondal
Publikováno v: O’shaughnessy, J, Petrakova, K, Sonke, G S, Conte, P, Arteaga, C L, Cameron, D A, Hart, L L, Villanueva, C, Jakobsen, E, Beck, J T, Lindquist, D, Souami, F, Mondal, S, Germa, C & Hortobagyi, G N 2017, ' Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial ', Breast cancer research and treatment . https://doi.org/10.1007/s10549-017-4518-8
Breast Cancer Research and Treatment
Purpose Determine the efficacy and safety of first-line ribociclib plus letrozole in patients with de novo advanced breast cancer. Methods Postmenopausal women with HR+ , HER2− advanced breast cancer and no prior systemic therapy for advanced disea
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49235fc434d9b04769919f70390e2b93
https://doi.org/10.1007/s10549-017-4518-8
Zobrazit plný text záznamu
10
Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib
Autor: B. Hewes, G. Caponigro, S.J. Scherer, Samit Hirawat, C. Germa, Pabak Mukhopadhyay, M. Miller
Publikováno v: Annals of Oncology
The treatment landscape for advanced breast cancer has changed radically over the last 30–40 years with the refinement of surgical and radiographic techniques, approval of a range of chemotherapy regimens in the adjuvant and metastatic settings, an
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5ada953fc0144e5b6e2cf20bbd18600
https://doi.org/10.1093/annonc/mdx226
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje